ClinicalTrials.gg
CompletedNCT05530954Updated Sep 26, 2023

Direct Pulp Capping in Primary Molars

A Phase 3 interventional study of Mineral trioxide aggregate (MTA) and Hard setting Calcium Hydroxide (Dycal) in Direct Pulp Capping, sponsored by Mansoura University. Completed at 1 site in Egypt. Open to participants aged 4 Years to 7 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-26.

Sponsored by Mansoura University · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Jan 2022, registered Sep 2022).
Phase
Phase 3
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
4 Years to 7 Years
Sex
All
01

Study summary

The purpose of this study is to Assess the effect of MTA and hard setting Calcium Hydroxide (Dycal) on the clinical and radiographic outcome of direct pulp capping in primary molars and evaluate overall success rate of direct pulp capping in primary molars.

Read the detailed description

After informed consent, baseline clinical and radiographic assessment will be obtained and recorded in patient examination sheet.

Participants who met the inclusion criteria were randomly allocated to two groups (n = 26/group, N = 52 in total) according to the capping martials using the envelope randomization method.

2 study groups according to capping material that will be used (Dycal or MTA) and each group will be divided to 2 subgroups according to site of exposure axial or pulpal.

All patients were recalled and their treated molars were evaluated clinically and radiographically at 3months, 6months, 9months ,12months follow up periods.

02

Conditions studied

  • Direct Pulp Capping

Keywords

  • primary dentition
  • MTA
  • Dycal
  • bioactive material
  • deciduous dentition
  • Direct pulp capping
03

In context

Lead sponsor

Mansoura University is the lead sponsor of 1,115 studies on the registry; 184 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years to 7 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cooperative child and compliant parent.
  • Complete physical and mental health.
  • Children who are known to be healthy and free from systemic diseases.
  • Primary molars with deep carious lesions leading to pathological exposure but with no signs or symptoms of irreversible pulpitis or necrosis such as spontaneous pain, tenderness to percussion, abscess, fistula, periodontal tissue swelling, or abnormal tooth mobility.

Exclusion criteria

Exclusion Criteria:

  • A deep carious lesion in close proximity to the pulp with an intact lamina dura.
  • Absence of widening of periodontal membrane space or radiolucency at the furcation and periapical region.
  • Absence of pulpal calcifications, obliteration of the pulp and root canal, or internal/external root resorption.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
52 participants (actual)

Study arms

  • Active comparator
    Mineral trioxide aggregate (MTA)

    * where the pulp tissue is exposed during final caries removal, hemostasis will be achieved by cavity irrigation with sterile saline solution for up to 4 minutes till control of bleeding * Teeth with pulp exposure less than 1mm in diameter surrounded by sound dentin will be candidates for direct pulp capping * Following the removal of the saline, the exposed pulp will be irrigated with 17% EDTA solution (Prevest Direct, India) for 1 minute * According to site of exposure, the groups will be further subdivided into Group A (n=13) with exposure in pulpal floor and Group B (n=13) with exposure in axial wall of the cavity. * Exposed pulp will be covered with fast set MTA paste after cavity dryness with sterile cotton pellet then the tooth will be restored with Self-cured glass ionomer restorative material (SDI Riva self-cure, Australia) and tooth will be covered by stainless steel crown

    Other: Mineral trioxide aggregate (MTA)

  • Active comparator
    Hard setting Calcium Hydroxide (Dycal)

    * where the pulp tissue is exposed during final caries removal, hemostasis will be achieved by cavity irrigation with sterile saline solution for up to 4 minutes till control of bleeding * Teeth with pulp exposure less than 1mm in diameter surrounded by sound dentin will be candidates for direct pulp capping * Following the removal of the saline, the exposed pulp will be irrigated with 17% EDTA solution (Prevest Direct, India) for 1 minute * According to site of exposure, the groups will be further subdivided into Group A (n=13) with exposure in pulpal floor and Group B (n=13) with exposure in axial wall of the cavity. * Exposed pulp will be covered with Dycal paste after cavity dryness with sterile cotton pellet then the tooth will be restored with Self-cured glass ionomer restorative material (SDI Riva self-cure, Australia) and tooth will be covered by stainless steel crown

    Other: Hard setting Calcium Hydroxide (Dycal)

Interventions

  • OtherMineral trioxide aggregate (MTA)

    Materials for Vital Pulp Capping

    Also known as: BIO MTA, CERKAMED, Poland

  • OtherHard setting Calcium Hydroxide (Dycal)

    Materials for Vital Pulp Capping

    Also known as: Dycal, Promedica Urbical, Germany

06

What researchers measure

Primary outcomes

  1. clinical success of direct pulp capping treatment after 3 months follow up

    Presence of any of these clinical findings will be considered failure: pain on mastication or spontaneous pain, as reported by the patient, without clinical evidence of plaque retention around the crown margin denoting bad oral hygiene. pain on percussion on clinical examination . non-physiologic mobility. fistula or sinus tract.

    Time frame: 3 months

  2. clinical success of direct pulp capping treatment after 6 months follow up

    Presence of any of these clinical findings will be considered failure: pain on mastication or spontaneous pain, as reported by the patient, without clinical evidence of plaque retention around the crown margin denoting bad oral hygiene. pain on percussion on clinical examination . non-physiologic mobility. fistula or sinus tract.

    Time frame: 6 months follow up

  3. clinical success of direct pulp capping treatment after 9 months follow up

    Presence of any of these clinical findings will be considered failure: pain on mastication or spontaneous pain, as reported by the patient, without clinical evidence of plaque retention around the crown margin denoting bad oral hygiene. pain on percussion on clinical examination . non-physiologic mobility. fistula or sinus tract.

    Time frame: 9 months follow up

  4. clinical success of direct pulp capping treatment after 12 months follow up

    Presence of any of these clinical findings will be considered failure: pain on mastication or spontaneous pain, as reported by the patient, without clinical evidence of plaque retention around the crown margin denoting bad oral hygiene. pain on percussion on clinical examination . non-physiologic mobility. fistula or sinus tract.

    Time frame: 12 months follow up

  5. radiographic success of direct pulp capping treatment after 3 months follow up

    the absence of the following radiographic findings indicate the success of capping material in pulp therapy: * pathological internal or external root resorption. * PDL widening. * inter-radicular radiolucency formation postoperatively. * periapical radiolucency formation postoperatively.

    Time frame: 3 months follow up

  6. radiographic success of direct pulp capping treatment after 6 months follow up

    the absence of the following radiographic findings indicate the success of capping material in pulp therapy: * pathological internal or external root resorption. * PDL widening. * inter-radicular radiolucency formation postoperatively. * periapical radiolucency formation postoperatively.

    Time frame: 6 months follow up

  7. radiographic success of direct pulp capping treatment after 9 months follow up

    the absence of the following radiographic findings indicate the success of capping material in pulp therapy: * pathological internal or external root resorption. * PDL widening. * inter-radicular radiolucency formation postoperatively. * periapical radiolucency formation postoperatively.

    Time frame: 9 months follow up

  8. radiographic success of direct pulp capping treatment after 12 months follow up

    the absence of the following radiographic findings indicate the success of capping material in pulp therapy: * pathological internal or external root resorption. * PDL widening. * inter-radicular radiolucency formation postoperatively. * periapical radiolucency formation postoperatively.

    Time frame: 12 months follow up

07

Study locations

1 site
  • Outpatient clinic of the Department of Pediatric Dentistry, Faculty of Dentistry- Mansoura University
    Al Mansurah, Egypt
08

References and documents

Publications

  • Caicedo R, Abbott PV, Alongi DJ, Alarcon MY. Clinical, radiographic and histological analysis of the effects of mineral trioxide aggregate used in direct pulp capping and pulpotomies of primary teeth. Aust Dent J. 2006 Dec;51(4):297-305. doi: 10.1111/j.1834-7819.2006.tb00447.x. PubMed 17256303 ↗
  • Faraco IM Jr, Holland R. Response of the pulp of dogs to capping with mineral trioxide aggregate or a calcium hydroxide cement. Dent Traumatol. 2001 Aug;17(4):163-6. doi: 10.1034/j.1600-9657.2001.170405.x. PubMed 11585142 ↗
  • de Lourdes Rodrigues Accorinte M, Reis A, Dourado Loguercio A, Cavalcanti de Araujo V, Muench A. Influence of rubber dam isolation on human pulp responses after capping with calcium hydroxide and an adhesive system. Quintessence Int. 2006 Mar;37(3):205-12. PubMed 16536148 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05530954
Responsible party
Nayera tarek (PhD researcher of Pediatric Dentistry and Dental Public Health, Mansoura University, Mansoura University) — Principal investigator
First posted
Sep 7, 2022
Start date
Jan 1, 2022
Primary completion
May 27, 2023
Completion
Jun 6, 2023
Last update
Sep 26, 2023

Study contacts

S M Awad, PhD/Prof
study chair · Head of Pediatric Dentistry and Dental Public Health, Mansoura University
A Y El Hosainy, PhD
study director · Lecturer of Pediatric Dentistry, Faculty of Dentistry, Mansoura University
N T El Saied, MSc
principal investigator · PhD researcher at Faculty of Dentistry, Mansoura University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion